TAK - Conference and earnings call announcements

− Award supports emerging biomedical researchers globally focused on gastrointestinal and inflammatory diseases, neuroscience and oncology Takeda ((TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking research with a focus on emerging scientific leaders who are advancing the frontiers of scientific discovery and fostering innovation that has the potential to transform lives. In 2026, the Takeda Innovators in Science Award with Nature will recognize promising early-career scientists in the areas of gastrointestinal and inflammatory diseases, neuroscience, and oncology.

Approximately 300,000 Canadians are living with IBD, with the number projected to grow to 470,000 by 2035.1 TORONTO, Nov. 4, 2024 /CNW/ - Takeda Canada Inc. ("Takeda") announces new data highlighting the impact Inflammatory Bowel Disease (IBD) has on Canadians. The data reveals insights into how the disease affects daily life, the challenges to timely access to care and treatment, and the unmet need to prioritize mental health support for those living with IBD. The Takeda 300,000 Reasons Why Survey ["the survey"], conducted by Leger, a leading North American market research fi

The 2023 Winners are Ayble Health and IBDrelief TORONTO, Sept. 12, 2023 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce two winners of the 2023 Takeda Canada Digital Health Innovation Challenge, a competition to identify and support innovative digital health solutions to improve patient outcomes and experiences. This year's challenge winners are two patient-led organizations with disruptive digital solutions aimed at improving the patient journey in Inflammatory Bowel Disease (IBD), the most common forms being Ulcerative Colitis and Crohn's Disease. The two compan

Seeking innovative tech initiatives to execute within the Canadian healthcare ecosystemChallenge application period runs June 1 to June 24, 2023TORONTO, June 1, 2023 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce the launch of the Takeda Canada Digital Health Innovation Challenge, an initiative to identify disruptive digital health solutions and explore new partnerships to accelerate and transform patient care in Canada. In the second challenge, Takeda is collaborating with Plug and Play Alberta ("Plug and Play") to help broaden our reach and to harness their exp

HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only Once-a-Month – Every Three or Four Weeks – Subcutaneous Immunoglobulin (ScIG), is Now Approved for People Two Years of Age and Older with Primary Immunodeficiency Approval Supported by Pivotal Phase 3 Study that Demonstrated Reliable Infection Protection in Children 2-16 Years Old Takeda ((TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16 years old. HYQVIA is the only subcutaneous immune globulin (ScIG) infusion that can be a

TAK-003 Recommended for the Prevention of Dengue Disease Caused by Any Dengue Virus Serotype in Individuals Four Years of Age and Older in the EU and in Dengue-Endemic Countries Participating in the EU-M4all Procedure Positive Opinion for TAK-003 Based on 4.5 Years of Safety and Efficacy Data from Pivotal Phase 3 Trial of Over 20,000 Children and Adolescents Across Eight Dengue-Endemic Countries Marketing Authorization Expected in Coming Months in Europe Followed by Regulatory Decisions in Latin America and Asia Takeda ((TAK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of Takeda's dengu

The first rare disease policy in Canada aims to provide a holistic approach to managing rare diseases in Quebec TORONTO, June 7, 2022 /CNW/ - Takeda Canada Inc. ("Takeda Canada"), a values-based, R&D-driven biopharmaceutical leader, committed to discovering and delivering life-transforming treatments, welcomes Quebec's first policy for rare diseases.  This policy is an important first step in acknowledging the unique complexities faced by Quebecers living with rare diseases and the changes needed to ensure ensure patients have access to the care and treatments they deserve. "W

DUBAI, UAE, June 9, 2021 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) has introduced the "In Their Shoes" platform, an award-winning, immersive simulation program to promote greater awareness and empathy for patients with Inflammatory bowel disease (IBD), a condition to describe Crohn's disease and ulcerative colitis, to a group of healthcare providers in the Middle East the first time.  The subscription-based program launched with a two-day simulation where healthcare providers and Takeda employees learned about the condition most effectively and profoundly: by "living with it." The program utilized a mobile application to guide participants through some of the everyday struggles patients

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021. Investors and the general public are invited to listen to the live webcast with Christophe Weber, president and chief executive officer, here. A replay of the webcast will also be archived at the same location. A link to the webcast and slides for download will also be available on Takeda’s website at https://www.takeda.com/investors/ir-events/. ABOUT TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda Phar

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at Piper Sandler’s 32nd Annual Virtual Healthcare Conference: The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to be Answered into 2021 Panel Presentation Date: Tuesday, Dec 1, 2020 Time: 10:00 a.m. ET About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings In